Objective: Prescription opioids account for 40% of all U.S. opioid overdose deaths, and national efforts have intensified to reduce opioid prescriptions. However, little is known about the relationship between peripheral arterial disease (PAD) and high-risk opioid use. The objectives of this study were to evaluate the relationship between PAD and high opioid use and to assess whether PAD treatment has an impact on high opioid use.
Objective: Prescription opioids account for 40% of all U.S. opioid overdose deaths, and national efforts have intensified to reduce opioid prescriptions. However, little is known about the relationship between peripheral arterial disease (PAD) and high-risk opioid use. The objectives of this study were to evaluate the relationship between PAD and high opioid use and to assess whether PAD treatment has an impact on high opioid use.
Methods: We used the 2007 to 2015 Truven Marketscan database, a deidentified national private insurance claims database, to identify patients with two International Classification of Diseases, Ninth Revision diagnosis codes of PAD 2 months apart with at least 2 years of continuous enrollment. Critical limb ischemia (CLI) was defined as rest pain, ulcers, or gangrene. Our primary outcome was high opioid use, defined as two opioid prescriptions within a 1-year period. Opioid prescriptions were excluded if they were filled within 90 days of a PAD-related procedure, identified by Current Procedural Terminology codes for lower extremity open/endovascular revascularization or amputation.
Results: A total of 182,186 patients with PAD met the inclusion criteria, 27.1% of whom had CLI. Mean (standard deviation) follow-up was 5.29 (2.13) years. An average of 24.4% of patients with PAD met the high opioid use criteria in any given calendar year, with a decreasing trend for patients meeting criteria beginning in 2010 (P < .01; Fig) . Of high opioid users, 26.0% continued to meet criteria for 5 years. High opioid use was more common for patients with CLI (32.2% vs 21.4%; P < .01). During years of high opioid use, 5.9 6 5.3 yearly prescriptions were filled. By multivariate analysis, illicit drug use and back pain were the strongest predictors of high opioid use (P < .001; Table) . A new diagnosis of PAD increased high opioid use (21.3% before PAD diagnosis vs 26.9% after PAD diagnosis; P < .01). This association was seen for patients without CLI (20.2% to 24.1%; P < .01) and with CLI (27.5% to 37.7%; P < .01). A total of 45,028 patients (24.7%) underwent 88,229 PAD-related procedures. After exclusion of periprocedural opioid prescriptions (18% of all opioid prescriptions), the yearly percentage of high opioid users increased from 25.6% before treatment to 29.2% after treatment (P < .01).
Conclusions: Patients with PAD are at increased risk for high opioid use, with nearly one-quarter meeting described criteria. CLI additionally increases opioid use. PAD treatment does not appear to decrease high opioid use. In addition to heightened awareness and active opioid management, our findings warrant further investigation into causes and deterrence of high-risk opioid use Objective: Clinical differentiation of buttock claudication from pseudoclaudication (neuromuscular etiology) is often challenging, and it cannot be diagnosed noninvasively using standard ankle-brachial index with exercise. The aim of this study was to evaluate the reliability of exercise transcutaneous oximetry (ExTcPO 2 ) to accurately detect significant internal iliac artery (IIA) inflow stenosis.
Methods: Data from a prospectively maintained registry of consecutive patients undergoing ExTcPO 2 for evaluation of buttock and hip exertional discomfort as well as arterial imaging within 12 months were retrospectively analyzed. ExTcPO 2 was performed on a treadmill (10% slope; 2 mph speed), measured at buttocks, upper back, and calf (rest, with exercise) to document the baseline normal, degree of change with exercise, and recovery patterns. A Delta from Resting Oxygen Pressure (DROP; buttock-back TcPO 2 ) À15 mm Hg was considered significant. A blinded physician performed aortoiliac arterial stenosis quantification, and receiver operating characteristic curve analysis was used to determine sensitivity and specificity to diagnose severe inflow reduction (70%) based on a diagnostic DROP À15 mm Hg.
Results: There were 111 patients (male/female, 79/32; mean age, 70 years; range, 18-90 years) with available concomitant imaging (computed tomography angiography, 90; duplex ultrasound, 21) included in the study. Indications for testing were suspected vascular (82) or neuromuscular (29) symptoms. ExTcPO 2 study confirmed the clinical suspicion of the state of IIA inflow in 81% (91/111) of patients. DROP À15 mm Hg had a sensitivity, specificity, positive predictive value, and negative predictive value of 56%, 80%, 70%, and 68%, respectively, for prediction of severe IIA inflow reduction (P < .001; odds ratio, 1.107; 95% confidence interval, 1.066-1.150; C statistic, 0.73; standard error, 0.03; Fig 1) . Aortoiliac arterial reconstruction to treat severe IIA flow compromise was performed in 21 patients. Revascularization was direct antegrade in 17 patients (IIA percutaneous transluminal angioplasty/stenting, 6; aortoiliac stenting/endarterectomy, 11), direct retrograde (aortobi-iliac bypass) in 1, and indirect by increased collateral flow (profundaplasty) in 3. Postoperatively, symptom relief was noted in 20 of 21 patients and objectively demonstrated on ExTcPO 2 in 6 of 7 (Fig 2) . One patient did not improve clinically or on ExTcPO 2 after indirect revascularization. 
